Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Debt to Equity (2024 - 2025)

Apellis Pharmaceuticals has reported Debt to Equity over the past 2 years, most recently at $1.23 for Q4 2025.

  • Quarterly results put Debt to Equity at $1.23 for Q4 2025, down 21.8% from a year ago — trailing twelve months through Dec 2025 was $1.23 (down 21.8% YoY), and the annual figure for FY2025 was $1.23, down 21.8%.
  • Debt to Equity for Q4 2025 was $1.23 at Apellis Pharmaceuticals, up from $1.13 in the prior quarter.
  • Over the last five years, Debt to Equity for APLS hit a ceiling of $2.31 in Q2 2025 and a floor of $1.13 in Q3 2025.